Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
about
The Use of Gene Therapy for Ablation of Atrial Fibrillation.Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.Pharmacotherapy of atrial fibrillation: an old option with new possibilities.Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm S
P2860
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@ast
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@en
type
label
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@ast
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@en
prefLabel
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@ast
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@en
P2093
P1433
P1476
Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.
@en
P2093
Angelo Branzi
Cristian Martignani
Mauro Biffi
P304
P356
10.2165/00003495-200363140-00005
P577
2003-01-01T00:00:00Z
P6179
1049583614